Advanced Enzyme Technologies Limited
Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.
What Advanced files
- Others52
- Investor Meet40
- Updates19
- Board Meeting11
- PPTs9
- Dividend/Bonus9
Advanced Enzyme received requests from five members of its founding group, who hold no shares, to be reclassified as public shareholders. This move, pending approvals, simplifies the shareholder structure, reflecting their current disassociation from the company.
Advanced Enzyme Tech's board approved an open market buyback of shares worth up to ₹69.7 Cr, at a maximum price of ₹500 per share. This aims to acquire over 1.39 million shares, funded by internal resources. No new shares for 6 months post-buyback, reflecting capital management.
Advanced Enzyme Tech reported Q1 FY27 revenue of ₹189.8 Cr (+2% YoY) but PAT declined 5% to ₹38.6 Cr. Strong growth in Bio-Processing (+30% YoY) and Specialized Manufacturing (+41% YoY). Firm launched 'Wellfa' brand in India, targets B2C expansion.
Company's AGM approved re-appointment of Whole Time Director Mukund Kabra for five years. Pradip Shah was appointed as an Independent Director for five years. Statutory Auditors M S K A & Associates LLP were also re-appointed for a second five-year term, strengthening governance.
Advanced Enzyme Technologies has scheduled its 37th Annual General Meeting (AGM) to be held virtually. The company has sent its latest Integrated Annual Report and AGM Notice via web-links/QR codes. Shareholders must update KYC details for electronic dividend payments.